Cargando…

Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein

BACKGROUND: Serum alpha-fetoprotein (AFP) is the approved serum marker for hepatocellular carcinoma (HCC) screening. However, not all HCC patients show high (≥ 20 ng/mL) serum AFP, and the molecular mechanisms of HCCs with normal (< 20 ng/mL) serum AFP remain to be elucidated. Therefore, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Young-Joo, Aycheh, Habtamu Minassie, Han, Seonggyun, Chamberlin, John, Shin, Jaehang, Byun, Seyoun, Lee, Younghee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771076/
https://www.ncbi.nlm.nih.gov/pubmed/33371894
http://dx.doi.org/10.1186/s12920-020-00836-4
_version_ 1783629642142318592
author Jin, Young-Joo
Aycheh, Habtamu Minassie
Han, Seonggyun
Chamberlin, John
Shin, Jaehang
Byun, Seyoun
Lee, Younghee
author_facet Jin, Young-Joo
Aycheh, Habtamu Minassie
Han, Seonggyun
Chamberlin, John
Shin, Jaehang
Byun, Seyoun
Lee, Younghee
author_sort Jin, Young-Joo
collection PubMed
description BACKGROUND: Serum alpha-fetoprotein (AFP) is the approved serum marker for hepatocellular carcinoma (HCC) screening. However, not all HCC patients show high (≥ 20 ng/mL) serum AFP, and the molecular mechanisms of HCCs with normal (< 20 ng/mL) serum AFP remain to be elucidated. Therefore, we aimed to identify biological features of HCCs with normal serum AFP by investigating differential alternative splicing (AS) between HCCs with normal and high serum AFP. METHODS: We performed a genome-wide survey of AS events in 249 HCCs with normal (n = 131) and high (n = 118) serum AFP levels using RNA-sequencing data obtained from The Cancer Genome Atlas. RESULTS: In group comparisons of RNA-seq profiles from HCCs with normal and high serum AFP levels, 161 differential AS events (125 genes; ΔPSI > 0.05, FDR < 0.05) were identified to be alternatively spliced between the two groups. Those genes were enriched in cell migration or proliferation terms such as “the cell migration and growth-cone collapse” and “regulation of insulin-like growth factor (IGF) transport and uptake by IGF binding proteins”. Most of all, two AS genes (FN1 and FAM20A) directly interact with AFP; these relate to the regulation of IGF transport and post-translational protein phosphorylation. Interestingly, 42 genes and 27 genes were associated with gender and vascular invasion (VI), respectively, but only eighteen genes were significant in survival analysis. We especially highlight that FN1 exhibited increased differential expression of AS events (ΔPSI > 0.05), in which exons 25 and 33 were more frequently skipped in HCCs with normal (low) serum AFP compared to those with high serum AFP. Moreover, these events were gender and VI dependent. CONCLUSION: We found that AS may influence the regulation of transcriptional differences inherent in the occurrence of HCC maintaining normal rather than elevated serum AFP levels.
format Online
Article
Text
id pubmed-7771076
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77710762020-12-30 Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein Jin, Young-Joo Aycheh, Habtamu Minassie Han, Seonggyun Chamberlin, John Shin, Jaehang Byun, Seyoun Lee, Younghee BMC Med Genomics Research BACKGROUND: Serum alpha-fetoprotein (AFP) is the approved serum marker for hepatocellular carcinoma (HCC) screening. However, not all HCC patients show high (≥ 20 ng/mL) serum AFP, and the molecular mechanisms of HCCs with normal (< 20 ng/mL) serum AFP remain to be elucidated. Therefore, we aimed to identify biological features of HCCs with normal serum AFP by investigating differential alternative splicing (AS) between HCCs with normal and high serum AFP. METHODS: We performed a genome-wide survey of AS events in 249 HCCs with normal (n = 131) and high (n = 118) serum AFP levels using RNA-sequencing data obtained from The Cancer Genome Atlas. RESULTS: In group comparisons of RNA-seq profiles from HCCs with normal and high serum AFP levels, 161 differential AS events (125 genes; ΔPSI > 0.05, FDR < 0.05) were identified to be alternatively spliced between the two groups. Those genes were enriched in cell migration or proliferation terms such as “the cell migration and growth-cone collapse” and “regulation of insulin-like growth factor (IGF) transport and uptake by IGF binding proteins”. Most of all, two AS genes (FN1 and FAM20A) directly interact with AFP; these relate to the regulation of IGF transport and post-translational protein phosphorylation. Interestingly, 42 genes and 27 genes were associated with gender and vascular invasion (VI), respectively, but only eighteen genes were significant in survival analysis. We especially highlight that FN1 exhibited increased differential expression of AS events (ΔPSI > 0.05), in which exons 25 and 33 were more frequently skipped in HCCs with normal (low) serum AFP compared to those with high serum AFP. Moreover, these events were gender and VI dependent. CONCLUSION: We found that AS may influence the regulation of transcriptional differences inherent in the occurrence of HCC maintaining normal rather than elevated serum AFP levels. BioMed Central 2020-12-28 /pmc/articles/PMC7771076/ /pubmed/33371894 http://dx.doi.org/10.1186/s12920-020-00836-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jin, Young-Joo
Aycheh, Habtamu Minassie
Han, Seonggyun
Chamberlin, John
Shin, Jaehang
Byun, Seyoun
Lee, Younghee
Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein
title Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein
title_full Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein
title_fullStr Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein
title_full_unstemmed Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein
title_short Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein
title_sort differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771076/
https://www.ncbi.nlm.nih.gov/pubmed/33371894
http://dx.doi.org/10.1186/s12920-020-00836-4
work_keys_str_mv AT jinyoungjoo differentialalternativesplicingbetweenhepatocellularcarcinomawithnormalandelevatedserumalphafetoprotein
AT aychehhabtamuminassie differentialalternativesplicingbetweenhepatocellularcarcinomawithnormalandelevatedserumalphafetoprotein
AT hanseonggyun differentialalternativesplicingbetweenhepatocellularcarcinomawithnormalandelevatedserumalphafetoprotein
AT chamberlinjohn differentialalternativesplicingbetweenhepatocellularcarcinomawithnormalandelevatedserumalphafetoprotein
AT shinjaehang differentialalternativesplicingbetweenhepatocellularcarcinomawithnormalandelevatedserumalphafetoprotein
AT byunseyoun differentialalternativesplicingbetweenhepatocellularcarcinomawithnormalandelevatedserumalphafetoprotein
AT leeyounghee differentialalternativesplicingbetweenhepatocellularcarcinomawithnormalandelevatedserumalphafetoprotein